KLF4 inhibited PDA proliferation and metastasis through multiple pathways, including inhibition of the potential tumor protein Musashi 2 (MSI2), the stem cell-associated protein CD44, and the promotion of the cell cycle-dependent protein kinase inhibitor p27Kip1 [50, 52, 94]. This evidence concerns the gene CDKN1B and Patent ductus arteriosus.